The Immune System in Cushing’s Syndrome
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cushing's syndrome (CS), or chronic hypercortisolism, induces a variety of alterations in the immune system, often leading to severe clinical complications such as sepsis and opportunistic infections. Prolonged exposure to high levels of glucocorticoids (GC), changes in the circadian rhythm, and the comorbidities associated therewith all combine to cause profound changes in the immune profile of affected patients. While traditionally associated with generalized immune suppression, such changes actually comprise a much more complex scenario, sharing traits with chronic inflammatory disorders. Persistently increased levels of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα) and adipose tissue infiltration by immune cells lead to a chronic, nonresolving, inflammatory state. The combination of low-grade inflammation and selectively impaired immune response is thought to play a major role in the pathogenesis of clinical complications of CS, including diabetes, lipodystrophy, visceral adiposity, atherosclerosis, osteoporosis, and cognitive impairment. This dysregulation also explains rebound phenomena when CS is treated, involving new clinical complications sustained by an excessive immune response and autoimmunity. The aim of this review is to summarize the available evidence on the immune system in chronic hypercortisolism, while describing the main mechanisms of immune derangement and their role in the increased mortality and morbidity seen in this complex disease. A better understanding of immune system alterations in CS could help improve risk stratification, offer novel biomarkers, and provide the basis for more tailored therapies and post-remission follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hydrocortisone plus fludrocortisone for adults with septic shock.
Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705716 · Cited by 939
Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes
Reddy, P., Lent-Schochet, D., Ramakrishnan, N., McLaughlin, M., & Jialal, I. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.06.019 · Cited by 297
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Exogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224
Isidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Self-citationClayton, R. N., Jones, P. W., Reulen, R. C., Stewart, P. M., Hassan-Smith, Z. K., Ntali, G., Karavitaki, N., Dekkers, O. M., Pereira, A. M., Bolland, M., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30005-5 · Cited by 208
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
On behalf of ABC Group, Scillitani, A., Mazziotti, G., Di Somma, C., Moretti, S., Stigliano, A., Pivonello, R., Giustina, A., & Colao, A. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2588-y · Cited by 62
Research works printed but not linked: 93
- Vitale, 2017, Pituitary magnetic resonance imaging in Cushing's disease, Endocrine, 55, 691, 10.1007/s12020-016-1038-y · DOI
- Isidori, 2006, Ectopic ACTH syndrome, Front. Horm. Res., 35, 143, 10.1159/000094323 · DOI
- Isidori, 2015, Conventional and nuclear medicine imaging in ectopic Cushing's syndrome: a systematic review, J. Clin. Endocrinol. Metab., 100, 3231, 10.1210/JC.2015-1589 · DOI · Paper page
- Storr, 2004, Prepubertal Cushing's disease is more common in males, but there is no increase in severity at diagnosis, J. Clin. Endocrinol. Metab., 89, 3818, 10.1210/jc.2003-031531 · DOI · Paper page
- Alexandraki, 2009, The prevalence and characteristic features of cyclicity and variability in Cushing's disease, Eur. J. Endocrinol., 160, 1011, 10.1530/EJE-09-0046 · DOI · Paper page
- Newell-Price, 2006, Cushing's syndrome, Lancet, 367, 1605, 10.1016/S0140-6736(06)68699-6 · DOI · Paper page
- Steffensen, 2010, Epidemiology of Cushing's syndrome, Neuroendocrinology, 92, 1, 10.1159/000314297 · DOI · Paper page
- Pivonello, 2016, Complications of Cushing's syndrome: state of the art, Lancet Diabetes Endocrinol., 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
- Isidori, 2015, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect, Eur. J. Endocrinol., 173, R101, 10.1530/EJE-15-0308 · DOI
- Mazziotti, 2016, Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines, Endocrine, 54, 603, 10.1007/s12020-016-1146-8 · DOI
- Graversen, 2012, Mortality in Cushing's syndrome: a systematic review and meta-analysis, Eur. J. Intern. Med., 23, 278, 10.1016/j.ejim.2011.10.013 · DOI
- Clayton, 2011, Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J. Clin. Endocrinol. Metab., 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
- Pivonello, 2016, Metabolic alterations and cardiovascular outcomes of cortisol excess, Front. Horm. Res., 46, 54, 10.1159/000443864 · DOI
- Sbardella, 2018, Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas, Eur. J. Endocrinol., 178, 501, 10.1530/EJE-17-0986 · DOI · Paper page
- Valassi, 2019, High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry, Eur. J. Endocrinol., 181, 461, 10.1530/EJE-19-0464 · DOI · Paper page
- Lionakis, 2003, Glucocorticoids and invasive fungal infections, Lancet, 362, 1828, 10.1016/S0140-6736(03)14904-5 · DOI · Paper page
- Graham, 1984, Opportunistic infections in endogenous Cushing's syndrome, Ann. Intern. Med., 101, 334, 10.7326/0003-4819-101-3-334 · DOI · Paper page
- Ejaz, 2011, Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience, Cancer, 117, 4381, 10.1002/cncr.26029 · DOI · Paper page
- Ilias, 2005, Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health, J. Clin. Endocrinol. Metab., 90, 4955, 10.1210/jc.2004-2527 · DOI · Paper page
- Sarlis, 2000, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin, J. Clin. Endocrinol. Metab., 85, 42
- Isidori, 2006, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up, J. Clin. Endocrinol. Metab., 91, 371, 10.1210/jc.2005-1542 · DOI · Paper page
- Dimopoulos, 1992, Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer, Cancer, 69, 66, 10.1002/1097-0142(19920101)69:1<66::AID-CNCR2820690113>3.0.CO;2-2 · DOI
- Scheffel, 2010, Invasive fungal infections in endogenous Cushing's syndrome, Infect. Dis. Rep., 2
- Fareau, 2007, Hypercortisolemia and infection, Infect. Dis. Clin. N. Am., 21, 639, 10.1016/j.idc.2007.06.001 · DOI
- van Halem, 2017, Characteristics and mortality of pneumocystis pneumonia in patients with Cushing's syndrome: a plea for timely initiation of chemoprophylaxis, Open Forum Infect. Dis., 4, 10.1093/ofid/ofx002 · DOI
- Long, 2020, High risk of activation of latent tuberculosis infection in rheumatic disease patients, Infect. Dis. (Lond.), 52, 80, 10.1080/23744235.2019.1682187 · DOI
- Colao, 2000, Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease, Clin. Endocrinol., 53, 13, 10.1046/j.1365-2265.2000.01018.x · DOI · Paper page
- Takasu, 1993, Development of autoimmune thyroid dysfunction after bilateral adrenalectomy in a patient with Carney's complex and after removal of ACTH-producing pituitary adenoma in a patient with Cushing's disease, J. Endocrinol. Investig., 16, 697, 10.1007/BF03348914 · DOI
- Takasu, 1990, Exacerbation of autoimmune thyroid dysfunction after unilateral adrenalectomy in patients with Cushing's syndrome due to an adrenocortical adenoma, N. Engl. J. Med., 322, 1708, 10.1056/NEJM199006143222404 · DOI · Paper page
- da Mota, 2011, Overt immune dysfunction after Cushing's syndrome remission: a consecutive case series and review of the literature, J. Clin. Endocrinol. Metab., 96, E1670, 10.1210/jc.2011-1317 · DOI · Paper page
- Marino, 2005, Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves, J. Endocrinol. Investig., 28, 280, 10.1007/BF03345386 · DOI
- Ueland, 2001, Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis, Eur. J. Endocrinol., 145, 685, 10.1530/eje.0.1450685 · DOI · Paper page
- Aranda, 2017, Circulatory immune cells in Cushing syndrome: bystanders or active contributors to atherometabolic injury? A study of adhesion and activation of cell surface markers, Int. J. Endocrinol., 2017, 2912763, 10.1155/2017/2912763 · DOI
- Aranda, 2018, Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission, Clin. Endocrinol., 88, 415, 10.1111/cen.13521 · DOI
- Masri-Iraqi, 2014, Elevated white blood cell counts in Cushing's disease: association with hypercortisolism, Pituitary, 17, 436, 10.1007/s11102-013-0522-0 · DOI
- Jablonska, 2017, The regulation of pre-metastatic niche formation by neutrophils, Oncotarget, 8, 112132, 10.18632/oncotarget.22792 · DOI · Paper page
- Nakagawa, 1998, Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes, Circulation, 98, 2307, 10.1161/01.CIR.98.21.2307 · DOI · Paper page
- Ronchetti, 2018, How glucocorticoids affect the neutrophil life, Int. J. Mol. Sci., 19, 10.3390/ijms19124090 · DOI · Paper page
- Nakagawa, 1999, The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte, Blood, 93, 2730, 10.1182/blood.V93.8.2730 · DOI · Paper page
- Ricci, 2017, Role of the glucocorticoid-induced leucine zipper gene in dexamethasone-induced inhibition of mouse neutrophil migration via control of annexin A1 expression, FASEB J., 31, 3054, 10.1096/fj.201601315R · DOI
- Bergstrom, 2017, Annexin A1 in blood mononuclear cells from patients with coronary artery disease: its association with inflammatory status and glucocorticoid sensitivity, PLoS One, 12, 10.1371/journal.pone.0174177 · DOI
- Perretti, 2009, Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics, Br. J. Pharmacol., 158, 936, 10.1111/j.1476-5381.2009.00483.x · DOI · Paper page
- Bergquist, 2015, Impairment of neutrophilic glucocorticoid receptor function in patients treated with steroids for septic shock, Intensive Care Med. Exp., 3, 59, 10.1186/s40635-015-0059-9 · DOI
- Tripodi, 2017, Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors, Endocrine, 56, 298, 10.1007/s12020-016-1027-1 · DOI
- Jurberg, 2018, Neuroendocrine control of macrophage development and function, Front. Immunol., 9, 1440, 10.3389/fimmu.2018.01440 · DOI
- Aranda, 2015, Long-term remission and recurrence rate in a cohort of Cushing's disease: the need for long-term follow-up, Pituitary, 18, 142, 10.1007/s11102-014-0567-8 · DOI
- Getting, 2002, Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis, Arthritis Rheum., 46, 2765, 10.1002/art.10526 · DOI · Paper page
- Andersen, 2017, Melanocortin 2, 3 and 4 receptor gene expressions are downregulated in CD8(+) T cytotoxic lymphocytes and CD19(+) B lymphocytes in rheumatoid arthritis responding to TNF-alpha inhibition, Scand. J. Immunol., 86, 31, 10.1111/sji.12555 · DOI
- Getting, 2008, A role for MC3R in modulating lung inflammation, Pulm. Pharmacol. Ther., 21, 866, 10.1016/j.pupt.2008.09.004 · DOI
- Leoni, 2008, Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion, FASEB J., 22, 4228, 10.1096/fj.08-113886 · DOI
- Norman, 2003, ACTH and alpha-MSH inhibit leptin expression and secretion in 3T3-L1 adipocytes: model for a central-peripheral melanocortin-leptin pathway, Mol. Cell. Endocrinol., 200, 99, 10.1016/S0303-7207(02)00410-0 · DOI
- Roerink, 2017, Increased adipocyte size, macrophage infiltration, and adverse local adipokine profile in perirenal fat in Cushing's syndrome, Obesity (Silver Spring), 25, 1369, 10.1002/oby.21887 · DOI
- Lee, 2019, Active Cushing disease is characterized by increased adipose tissue macrophage presence, J. Clin. Endocrinol. Metab., 104, 2453, 10.1210/jc.2018-02552 · DOI
- Isidori, 2002, Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease, J. Clin. Endocrinol. Metab., 87, 1834
- Eddy, 2014, Glucocorticoids regulate natural killer cell function epigenetically, Cell. Immunol., 290, 120, 10.1016/j.cellimm.2014.05.013 · DOI
- Misale, 2018, Chromatin organization as an indicator of glucocorticoid induced natural killer cell dysfunction, Brain Behav. Immun., 67, 279, 10.1016/j.bbi.2017.09.004 · DOI
- Morgan, 2017, Distinct effects of dexamethasone on human natural killer cell responses dependent on cytokines, Front. Immunol., 8, 432, 10.3389/fimmu.2017.00432 · DOI
- Quatrini, 2018, Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells, Nat. Immunol., 19, 954, 10.1038/s41590-018-0185-0 · DOI
- Kronfol, 1996, Immune regulation in Cushing's syndrome: relationship to hypothalamic-pituitary-adrenal axis hormones, Psychoneuroendocrinology, 21, 599, 10.1016/S0306-4530(96)00021-2 · DOI
- Masera, 1999, Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome, Eur. J. Endocrinol., 140, 299, 10.1530/eje.0.1400299 · DOI
- Venneri, 2018, Circadian rhythm of glucocorticoid administration entrains clock genes in immune cells: a DREAM trial ancillary study, J. Clin. Endocrinol. Metab., 103, 2998, 10.1210/jc.2018-00346 · DOI · Paper page
- Minnetti, M. et al. Fixing the broken clock in adrenal disorders. Focus on glucocorticoids and chronotherapy. J. Endocrinol. (in press)
- Gadkari, 2018, Transcript- and protein-level analyses of the response of human eosinophils to glucocorticoids, Sci. Data, 5, 180275, 10.1038/sdata.2018.275 · DOI
- Wu, 2011, Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis, Science, 332, 243, 10.1126/science.1201475 · DOI · Paper page
- Lee, 2017, The eosinophil count tends to be negatively associated with levels of serum glucose in patients with adrenal Cushing syndrome, Endocrinol. Metab. (Seoul), 32, 353, 10.3803/EnM.2017.32.3.353 · DOI
- Oppong, 2013, Molecular mechanisms of glucocorticoid action in mast cells, Mol. Cell. Endocrinol., 380, 119, 10.1016/j.mce.2013.05.014 · DOI
- Vetillard, 2018, Glucocorticoid-induced leucine zipper: fine-tuning of dendritic cells function, Front. Immunol., 9, 1232, 10.3389/fimmu.2018.01232 · DOI
- Barahona, 2009, Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome, J. Clin. Endocrinol. Metab., 94, 3365, 10.1210/jc.2009-0766 · DOI · Paper page
- Valassi, 2012, Adipokines and cardiovascular risk in Cushing's syndrome, Neuroendocrinology, 95, 187, 10.1159/000330416 · DOI · Paper page
- Urwyler, 2017, Interleukin-1 antagonism decreases cortisol levels in obese individuals, J. Clin. Endocrinol. Metab., 102, 1712, 10.1210/jc.2016-3931 · DOI · Paper page
- Geer, 2014, Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism, Endocrinol. Metab. Clin. N. Am., 43, 75, 10.1016/j.ecl.2013.10.005 · DOI · Paper page
- Oliveira, 2020, Osteoporosis and osteoarthritis are two sides of the same coin paid for obesity, Nutrition, 70, 110486, 10.1016/j.nut.2019.04.001 · DOI
- De Larichaudy, 2012, TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism, Skelet. Muscle, 2, 2, 10.1186/2044-5040-2-2 · DOI · Paper page
- Crescioli, 2012, Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target, Eur. J. Cell Biol., 91, 139, 10.1016/j.ejcb.2011.09.011 · DOI
- Savino, 2016, Hormonal control of T-cell development in health and disease, Nat. Rev. Endocrinol., 12, 77, 10.1038/nrendo.2015.168 · DOI
- Kovalovsky, 2000, Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production, J. Neuroimmunol., 109, 23, 10.1016/S0165-5728(00)00298-8 · DOI
- Banuelos, 2016, BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis, Allergy, 71, 640, 10.1111/all.12840 · DOI
- Chen, 2004, Differential response of murine CD4+CD25+ and CD4+CD25− T cells to dexamethasone-induced cell death, Eur. J. Immunol., 34, 859, 10.1002/eji.200324506 · DOI · Paper page
- Suarez, 2006, Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids, Ann. Rheum. Dis., 65, 1512, 10.1136/ard.2005.049924 · DOI
- Pandolfi, 2013, Regulatory and effector T-cells are differentially modulated by dexamethasone, Clin. Immunol., 149, 400, 10.1016/j.clim.2013.09.008 · DOI
- Kasper, 2016, Empowering regulatory T cells in autoimmunity, Trends Mol. Med., 22, 784, 10.1016/j.molmed.2016.07.003 · DOI
- Gudbrandsdottir, 2018, Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia, Eur. J. Haematol., 100, 45, 10.1111/ejh.12978 · DOI
- Cupps, 1985, Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation, J. Clin. Invest., 75, 754, 10.1172/JCI111757 · DOI · Paper page
- Cushing, 1932, Further concerning a parasympathetic center in the interbrain: VII. The effect of intraventricularly-injected histamine, Proc. Natl. Acad. Sci. U. S. A., 18, 500, 10.1073/pnas.18.7.500 · doi:10.1073/pnas.18.7.500
- Singer, 2016, The new sepsis consensus definitions (Sepsis-3): the good, the not-so-bad, and the actually-quite-pretty, Intensive Care Med., 42, 2027, 10.1007/s00134-016-4600-4 · DOI
- Warny, 2018, Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study, PLoS Med., 15, 10.1371/journal.pmed.1002685 · DOI · Paper page
- Bermejo-Martin, 2018, Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease), J. Clin. Med., 7, 10.3390/jcm7110400 · DOI
- Drifte, 2013, Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome, Crit. Care Med., 41, 820, 10.1097/CCM.0b013e318274647d · DOI · Paper page
- Rubio, 2019, Current gaps in sepsis immunology: new opportunities for translational research, Lancet Infect. Dis., 19, e422, 10.1016/S1473-3099(19)30567-5 · DOI · Paper page
- Chaudhary, 2017, Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort, Crit. Care, 21, 185, 10.1186/s13054-017-1767-1 · DOI
- Venkatesh, 2018, Long-term outcomes of the ADRENAL trial, N. Engl. J. Med., 378, 1744, 10.1056/NEJMc1803563 · DOI
- Fang, 2019, Association of corticosteroid treatment with outcomes in adult patients with sepsis: a systematic review and meta-analysis, JAMA Intern. Med., 179, 213, 10.1001/jamainternmed.2018.5849 · DOI · Paper page
- Venkatesh, 2019, Hydrocortisone compared with placebo in patients with septic shock satisfying the sepsis-3 diagnostic criteria and APROCCHSS study inclusion criteria: a post hoc analysis of the ADRENAL trial, Anesthesiology, 131, 1292, 10.1097/ALN.0000000000002955 · DOI
Cited by
Clinical Biology of the Pituitary Adenoma
Melmed, S., Kaiser, U. B., Lopes, M. B., Bertherat, J., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 321
The multiple roles of life stress in metabolic disorders
Kivimäki, M., Bartolomucci, A., & Kawachi, I. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00746-8 · Cited by 297
Approach to the Patient: Diagnosis of Cushing Syndrome
Savas, M., Mehta, S., Agrawal, N., van Rossum, E. F. C., & Feelders, R. A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac492 · Cited by 91
Hasenmajer, V., Sbardella, E., Sciarra, F., Simeoli, C., Pivonello, C., Ceccato, F., Pofi, R., Minnetti, M., Rizzo, F., Ferrari, D., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105462 · Cited by 29
Self-citationFerrari, D., Bonaventura, I., Simeoli, C., Tomaselli, A., Vincenzi, L., De Alcubierre, D., Sciarra, F., Rizzo, F., Cerroni, L., Di Paola, N., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf206 · Cited by 28
Self-citation
Metadata
- Authors
- Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Issue
- 9
- Pages
- 655-669
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W3023302320
- Cited by
- 147
- References
- 7
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Immune System in Cushing’s Syndrome. https://app.cochat.ai/papers/10.1016/j.tem.2020.04.004
- The paper
- Hasenmajer, V., Sbardella, E., Sciarra, F., Minnetti, M., Isidori, A. M., & Venneri, M. A. (2020). The Immune System in Cushing’s Syndrome. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2020.04.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.